KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Karyopharm Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.35−0.04 (-11.30%)
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
96.1%
22M of 23M shares
Institutional holders
96
34 new, 14 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 19 sales
Net sold $349.32K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| The Goldman Sachs Group, Inc. | 991,364 | 5.10% | 13G (passive) | Mar 31, 2026 |
| Robert Atchinson | 6,551,055 | 5.18% | 13G (passive) | Dec 31, 2024 |
| Peter Kolchinsky | 2,302,504 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah | 2,078,913 | 9.90% | 13G (passive) | Mar 26, 2026 |
| Michael Cho | 2,073,517 | 8.60% | 13G (passive) amendment | Mar 31, 2026 |
| Commodore Capital LP | 1,950,000 | 9.90% | 13G (passive) | Mar 26, 2026 |
| Affinity Asset Advisors, LLC | 1,713,092 | 8.60% | 13G (passive) amendment | Jan 22, 2026 |
| James Silverman | 1,569,002 | 9.48% | 13G (passive) | Oct 10, 2025 |
| T. Rowe Price Investment Management, Inc. | 1,539,147 | 6.60% | 13G (passive) amendment | May 31, 2026 |
| Phillip Gross | 1,536,736 | 6.78% | 13G (passive) amendment | Jun 30, 2026 |
| Goldman Sachs & Co. LLC | 1,429,198 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| Israel A. Englander | 1,297,297 | 5.70% | 13G (passive) | Aug 31, 2026 |
| BlackRock, Inc. | 1,266,084 | 5.60% | 13G (passive) | Jun 30, 2026 |
| Millennium Group Management LLC | 1,008,662 | 5.50% | 13G (passive) | Feb 4, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KPTI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 1,917,354 | 8.45% | $18.73M | – | 0.16% |
| Adage Capital Partners Gp, L.L.C. | 1,521,322 | 6.71% | $14.86M | −285,000 | 0.02% |
| Acorn Capital Advisors, LLC | 1,518,113 | 6.69% | $14.83M | +1,230,287 | 4.05% |
| Goldman Sachs Group Inc | 1,424,658 | 6.28% | $13.92M | +477,079 | 0.00% |
| BlackRock, Inc. | 1,418,799 | 6.26% | $13.86M | +1,173,900 | 0.00% |
| Kalehua Capital Management LLC | 1,371,288 | 6.05% | $13.40M | New | 4.27% |
| Vanguard Capital Management LLC | 958,979 | 4.23% | $9.37M | +219,234 | 0.00% |
| Catalio Capital Management, LP | 940,855 | 4.15% | $9.19M | +43,146 | 1.73% |
| Avidity Partners Management LP | 924,487 | 4.08% | $9.03M | −2,995 | 1.45% |
| T. Rowe Price Investment Management, Inc. | 786,309 | 3.47% | $7.68K | −755,781 | 0.01% |
| Two Sigma Investments, LP | 695,264 | 3.07% | $6.79M | +544,032 | 0.00% |
| NEA Management Company, LLC | 576,780 | 2.54% | $5.64M | New | 0.35% |
| Geode Capital Management, LLC | 531,231 | 2.34% | $5.19M | +325,098 | 0.00% |
| Ghisallo Capital Management LLC | 500,000 | 2.20% | $4.89M | New | 0.10% |
| Soleus Capital Management, L.P. | 440,000 | 1.94% | $4.30M | – | 0.15% |
| UBS Group AG | 353,545 | 1.56% | $3.45M | +159,528 | 0.00% |
| State Street Corp | 325,991 | 1.44% | $3.18M | +245,249 | 0.00% |
| Affinity Asset Advisors, LLC | 312,500 | 1.38% | $3.05M | −187,500 | 0.14% |
| Brevan Howard Capital Management LP | 309,817 | 1.37% | $3.03M | +97,450 | 0.02% |
| Millennium Management LLC | 305,676 | 1.35% | $2.99M | −114,895 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 22M | 96.1% | 34 / 30 | 14 / 14 | 9M | 5M |
| Q1 2026 | 76 | 18M | 79.6% | 24 / 31 | 10 / 15 | 12M | 3M |
| Q4 2025 | 69 | 10M | 44.3% | 27 / 19 | 5 / 9 | 7M | 0M |
| Q3 2025 | 51 | 3M | 13.0% | 7 / 7 | 20 / 5 | 0M | 2M |
| Q2 2025 | 49 | 4M | 19.4% | 12 / 12 | 6 / 10 | 1M | 0M |
| Q1 2025 | 47 | 3M | 14.4% | 47 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KPTI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 677,729 | 2.99% | $6.62M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 490,317 | 2.16% | $4.79M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 435,070 | 1.92% | $4.25M | 0.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 263,084 | 1.16% | $2.57M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 216,009 | 0.95% | $414.74K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 153,539 | 0.68% | $1.50M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 94,581 | 0.42% | $860.69K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 81,441 | 0.36% | $795.68K | 0.01% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 66,938 | 0.30% | $653.98K | 0.04% | Jun 30, 2026 |
| Ultra-Small Company Fund | 49,873 | 0.22% | $487.26K | 0.49% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 48,520 | 0.21% | $93.16K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 37,232 | 0.16% | $363.76K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 34,152 | 0.15% | $310.78K | 0.00% | May 31, 2026 |
| Nomura Healthcare Fund | 33,333 | 0.15% | $325.66K | 0.04% | Jun 30, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 32,185 | 0.14% | $61.80K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard A. Paulson | President and CEO, Director | 269,747 | 1.19% | May 15, 2026 |
| Kristin Abate | Chief Accounting Officer | 23,782 | 0.10% | Sep 2, 2026 |
| Stuart Poulton | EVP, Chief Development Officer | 94,632 | 0.42% | Jul 30, 2026 |
| Reshma Rangwala | EVP & Chief Medical Officer | 56,829 | 0.25% | May 15, 2026 |
| Sohanya Roshan Cheng | EVP & Chief Commercial Officer | 107,940 | 0.48% | May 15, 2026 |
| Michael Mano | EVP, CLO&Secretary | 94,398 | 0.42% | May 15, 2026 |
| Lori Macomber | EVP, CFO & Treasurer | 85,105 | 0.38% | Feb 4, 2026 |
| Christy J. Oliger | Director | 15,508 | 0.07% | May 26, 2026 |
| Chen Schor | Director | 15,508 | 0.07% | May 26, 2026 |
| Barry E. Greene | Director | 16,415 | 0.07% | May 26, 2026 |
| Garen G. Bohlin | Director | 18,517 | 0.08% | May 26, 2026 |
| Deepika Pakianathan | Director | 15,508 | 0.07% | May 26, 2026 |
| Zhen Su | Director | 15,508 | 0.07% | May 26, 2026 |
| Mansoor Raza Mirza | Director | 17,121 | 0.08% | May 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kristin Abate Chief Accounting Officer | Sep 1, 2026 | Sale | −19 | $2.02 | $38 | 23,782 |
| Stuart Poulton EVP, Chief Development Officer | Jul 28, 2026 | Sale | −189 | $7.10 | $1.34K | 94,632 |
| Christy J. Oliger Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Garen G. Bohlin Director | May 21, 2026 | Award | +15,508 | – | – | 18,517 |
| Zhen Su Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Chen Schor Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Deepika Pakianathan Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Barry E. Greene Director | May 21, 2026 | Award | +15,508 | – | – | 16,415 |
| Stuart Poulton EVP, Chief Development Officer | May 14, 2026 | Sale | −403 | $9.50 | $3.83K | 94,821 |
| Kristin Abate Chief Accounting Officer | May 14, 2026 | Sale | −53 | $9.50 | $504 | 23,801 |
| Michael Mano EVP, CLO&Secretary | May 14, 2026 | Sale | −266 | $9.50 | $2.53K | 94,398 |
| Richard A. Paulson President and CEO, Director | May 14, 2026 | Sale | −2,203 | $9.50 | $20.93K | 269,747 |
| Reshma Rangwala EVP & Chief Medical Officer | May 14, 2026 | Sale | −408 | $9.50 | $3.88K | 56,829 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | May 14, 2026 | Sale | −324 | $9.50 | $3.08K | 107,940 |
| Stuart Poulton EVP, Chief Development Officer | May 13, 2026 | Award | +896 | – | – | 95,224 |
| Kristin Abate Chief Accounting Officer | May 13, 2026 | Award | +121 | – | – | 23,854 |
| Michael Mano EVP, CLO&Secretary | May 13, 2026 | Award | +700 | – | – | 94,664 |
| Richard A. Paulson President and CEO, Director | May 13, 2026 | Award | +4,920 | – | – | 271,950 |
| Reshma Rangwala EVP & Chief Medical Officer | May 13, 2026 | Award | +947 | – | – | 57,237 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | May 13, 2026 | Award | +947 | – | – | 108,264 |
| Reshma Rangwala EVP & Chief Medical Officer | Apr 21, 2026 | Sale | −449 | $8.94 | $4.01K | 56,290 |
| Stuart Poulton EVP, Chief Development Officer | Mar 2, 2026 | Sale | −5,101 | $9.41 | $48.00K | 94,328 |
| Kristin Abate Chief Accounting Officer | Mar 2, 2026 | Sale | −559 | $9.41 | $5.26K | 22,063 |
| Michael Mano EVP, CLO&Secretary | Mar 2, 2026 | Sale | −3,526 | $9.41 | $33.18K | 93,964 |
| Richard A. Paulson President and CEO, Director | Mar 2, 2026 | Sale | −12,361 | $9.41 | $116.32K | 267,030 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Mar 2, 2026 | Sale | −4,604 | $9.41 | $43.32K | 107,317 |
| Reshma Rangwala EVP & Chief Medical Officer | Mar 2, 2026 | Sale | −5,066 | $9.41 | $47.67K | 56,739 |
| Stuart Poulton EVP, Chief Development Officer | Feb 17, 2026 | Sale | −378 | $8.63 | $3.26K | 99,429 |
| Richard A. Paulson President and CEO, Director | Feb 5, 2026 | Award | +81,060 | – | – | 279,391 |
| Lori Macomber EVP, CFO & Treasurer | Feb 3, 2026 | Sale | −1,626 | $6.30 | $10.24K | 85,105 |
| Lori Macomber EVP, CFO & Treasurer | Jan 31, 2026 | Award | +32,415 | – | – | 86,731 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Jan 31, 2026 | Award | +32,415 | – | – | 111,921 |
| Michael Mano EVP, CLO&Secretary | Jan 31, 2026 | Award | +32,415 | – | – | 97,490 |
| Stuart Poulton EVP, Chief Development Officer | Jan 31, 2026 | Award | +32,415 | – | – | 99,807 |
| Reshma Rangwala EVP & Chief Medical Officer | Jan 31, 2026 | Award | +32,415 | – | – | 61,805 |
| Kristin Abate Chief Accounting Officer | Jan 28, 2026 | Sale | −50 | $7.03 | $352 | 22,622 |
| Kristin Abate Chief Accounting Officer | Jan 27, 2026 | Award | +92 | – | – | 22,672 |
| Kristin Abate Chief Accounting Officer | Jan 21, 2026 | Sale | −265 | $5.96 | $1.58K | 22,580 |
| Richard A. Paulson President and CEO, Director | Oct 15, 2025 | Award | +114,285 | – | – | 198,331 |
| Michael Mano SVP, General Counsel&Secretary | Oct 15, 2025 | Award | +43,650 | – | – | 65,075 |
| Lori Macomber EVP, CFO & Treasurer | Oct 15, 2025 | Award | +43,650 | – | – | 54,316 |
| Kristin Abate Chief Accounting Officer | Oct 15, 2025 | Award | +12,799 | – | – | 22,845 |
| Stuart Poulton EVP, Chief Development Officer | Oct 15, 2025 | Award | +39,682 | – | – | 67,392 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Oct 15, 2025 | Award | +43,650 | – | – | 79,506 |
| Kristin Abate Chief Accounting Officer | Oct 1, 2025 | Sale | −362 | $6.30 | $2.28K | 10,046 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Sep 15, 2025 | Sale | −325 | $6.43 | $2.09K | 35,856 |
| Richard A. Paulson President and CEO, Director | Sep 15, 2025 | Sale | −1,257 | $6.43 | $8.08K | 84,046 |
| Michael Mano SVP, General Counsel&Secretary | Sep 15, 2025 | Sale | −234 | $6.43 | $1.50K | 21,425 |
| Kristin Abate Chief Accounting Officer | Sep 15, 2025 | Sale | −23 | $6.43 | $148 | 10,408 |
| Stuart Poulton EVP, Chief Development Officer | Sep 15, 2025 | Sale | −401 | $6.43 | $2.58K | 27,710 |
| Reshma Rangwala EVP & Chief Medical Officer | Sep 15, 2025 | Sale | −408 | $6.43 | $2.62K | 29,390 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Sep 12, 2025 | Award | +945 | – | – | 36,181 |
| Richard A. Paulson President and CEO, Director | Sep 12, 2025 | Award | +2,800 | – | – | 85,303 |
| Michael Mano SVP, General Counsel&Secretary | Sep 12, 2025 | Award | +612 | – | – | 21,659 |
| Kristin Abate Chief Accounting Officer | Sep 12, 2025 | Award | +46 | – | – | 10,431 |
| Stuart Poulton EVP, Chief Development Officer | Sep 12, 2025 | Award | +888 | – | – | 28,111 |
| Reshma Rangwala EVP & Chief Medical Officer | Sep 12, 2025 | Award | +945 | – | – | 29,798 |
| Kristin Abate Chief Accounting Officer | Sep 3, 2025 | Sale | −12 | $6.78 | $81 | 9,463 |
| Stuart Poulton EVP, Chief Development Officer | Jul 29, 2025 | Sale | −191 | $4.37 | $835 | 27,223 |
| Kristin Abate Chief Accounting Officer | Jul 22, 2025 | Sale | −238 | $4.00 | $952 | 9,475 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.